Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633563 | 0.84 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15633404 | 0.84 | PDE4A (0.35) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15633484 | 0.79 | — | — | |
| SCHEMBL19364147 | 0.75 | — | — | |
| SCHEMBL20349168 | 0.74 | HCAR2 (0.32) | HCAR2 | |
| SCHEMBL20349170 | 0.74 | ALOX15 (0.33) | HCAR2 | |
| SCHEMBL25477654 | 0.73 | ALDH1A1 (0.35) | TAAR1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL13990867 | 0.72 | ALDH1A1 (0.34) | TAAR1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL17773615 | 0.72 | ALDH1A1 (0.34) | TAAR1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15633534 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9718819-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170173015-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | TAAR1 4155/4885ALDH1A1 1343/4885CYP1A2 1150/4885 |
| US-20170173015-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | TYMP, RNGTT, REV1 | TAAR1 3413/4885ALDH1A1 329/4885CYP1A2 81/4885 |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | TYMP, RNGTT, REV1 | TAAR1 3413/4885ALDH1A1 329/4885CYP1A2 81/4885 |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | TAAR1 4155/4885ALDH1A1 1343/4885CYP1A2 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.